Primary Infection by E. multilocularis Induces Distinct Patterns of Cross Talk between Hepatic Natural Killer T Cells and Regulatory T Cells in Mice

Yarahmadov, Tural; Wang, Junhua; Sánchez-Taltavull, Daniel; Rojas, Cristian A. Álvarez; Brodie, Tess M.; Büchi, Isabel; Keogh, Adrian; Gottstein, Bruno; Stroka, Deborah; Beldi, Guido

doi:10.1128/iai.00174-22

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of albendazole with novel materials (such as solid dispersion 60 , liposomes 61 , nanoparticles 62 , 63 , microspheres 50 , and self-microemulsion 64 , 65 ) has been reported to enhance hepatic drug concentrations, thereby facilitating disease control; however, certain limitations still exist 66 . Moreover, during investigation on the correlation between HE and immune sites, we notably revealed that the downregulation of PD-1/PD-L1 in the liver can effectively impede the pathophysiological progression caused by parasites through modulation of natural killer T (NKT) cells and regulatory T cells (Tregs), as evidenced by in vivo animal studies 67 , 68 . This presented a novel perspective for the treatment of HE.…”

Section: Discussionmentioning

confidence: 99%

Characterization of research trends and prospects on hepatic echinococcosis over the past forty years: a bibliometric analysis

Li,

Su,

Wang

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

Background: The distribution of hepatic echinococcosis (HE) is extensive, significantly impacting public health and economic development. Therefore, analyzing global collaboration networks and tracking developmental trends over the past four decades are crucial. This study aimed to demonstrate collaboration in the field of HE and explore key topics and future directions. Materials and Methods: Bibliometric analyses were conducted using CiteSpace, Bibliometrix package of R, and VOSviewer software on HE-related studies from the Web of Science Core Collection published before August 1, 2023. Results: This study identified 2,605 records published in 196 journals by 9,860 authors from 2,607 institutes in 90 countries. Publications significantly notably increased in 2021. Developing countries like Turkey and China made notable contributions, while developed countries like the USA had higher average citation rates. The largest nodes in every cluster of the collaboration network were Hacettepe University, Tehran University, Xinjiang Medical University, Salford University, and the University of Pavia, and the top-producing authors were Wen H, Vuitton DA, Gottstein B, and Craig PS. Keyword co-occurrence analysis suggested that surgical techniques and novel drugs targeting combined immune checkpoints are the main therapeutic approaches in the future. Conclusion: Although developing countries had significantly contributed to publications on HE, the citation rate for individual articles from developed countries was significantly higher. Additionally, advancements in surgical techniques and novel drugs targeting combined immune checkpoints may emerge as the next research focus and developmental direction.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of research trends and prospects on hepatic echinococcosis over the past forty years: a bibliometric analysis

Li,

Su,

Wang

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

Chemotherapy for the treatment of alveolar echinococcosis: Where are we?

Autier,

Robert-Gangneux,

Dion

2024

Parasite

View full text Add to dashboard Cite

Alveolar echinococcosis (AE) is a severe liver disease due to infection with the Echinococcus multilocularis larval stage, called the metacestode. Management of AE is based on benzimidazole chemotherapy (albendazole or mebendazole), associated with surgery when possible. Benzimidazoles are the only compounds recommended for the treatment of AE; however, these are parasitostatic, which means that the parasite can resume growth when treatment is interrupted. Also, benzimidazoles can cause liver dysfunction which may prevent their use. Numerous drugs have been reported to have in vitro activity against E. multilocularis, but few had satisfactory in vivo activity, and none were clearly more effective than benzimidazoles. These drugs belong to various therapeutic categories including anti-infective agents (e.g. amphotericin B, mefloquine, pentamidine derivatives), anti-neoplastic compounds (e.g. imatinib, nilotinib, bortezomib), plant-extracted compounds (e.g. thymol, crocin, carvacrol) and others (e.g. metformin, verapamil, thiaclopride). These treatments are generally of limited interest due to their toxicity, their unfavorable pharmacokinetics, or the scarcity of studies involving humans. Apart from benzimidazoles, only amphotericin B, mefloquine and nitazoxanide have been reported to be used for human AE treatment, with unsatisfactory results. Few studies have aimed at developing innovative strategies for AE drug therapy, such as vectorization of drugs using nanoparticles. Altogether, this review emphasizes the urgent need for new therapeutic strategies in AE management, for which there is currently no curative chemotherapy.

show abstract

Primary Infection by E. multilocularis Induces Distinct Patterns of Cross Talk between Hepatic Natural Killer T Cells and Regulatory T Cells in Mice

Cited by 2 publications

References 53 publications

Characterization of research trends and prospects on hepatic echinococcosis over the past forty years: a bibliometric analysis

Characterization of research trends and prospects on hepatic echinococcosis over the past forty years: a bibliometric analysis

Chemotherapy for the treatment of alveolar echinococcosis: Where are we?

Contact Info

Product

Resources

About